Copenhagen, 2013-08-06 10:32 CEST (GLOBE NEWSWIRE) --
ALK will hold a conference call for analysts and investors that day at 2.00 p.m. (CET) at which Jens Bager, President and CEO, Flemming Pedersen, CFO, and Henrik Jacobi, EVP R&D, will review the financial results, the outlook and key results from the recently completed pivotal MERIT and MITRA trials with ALK's new allergy immunotherapy (AIT) tablet for the treatment of house dust mite-induced respiratory diseases.
Participants in the conference call are kindly requested to call in before 1.55 p.m. (CET). Danish participants should call in on tel. +45 7026 5040 or +45 7027 9009 and international participants should call in on tel. +44 (0) 20 8817 9301.
The conference call will also be webcast on our website www.alk-abello.com/investor, where the related presentation will be available shortly before the conference call begins.
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. + 45 4574 7901, mobile + 45 2064 1143